Page of

The epidemiology of ankylosing spondylitis, axial spondyloarthritis, and back pain 

The epidemiology of ankylosing spondylitis, axial spondyloarthritis, and back pain
Chapter:
The epidemiology of ankylosing spondylitis, axial spondyloarthritis, and back pain
Source:
Axial Spondyloarthritis (Oxford Rheumatology Library)
Author(s):

Stefan Siebert

, Sengupta Raj

, and Alexander Tsoukas

DOI:
10.1093/med/9780198755296.003.0003

Low back pain is a leading cause of disability worldwide. The prevalence of inflammatory back pain (IBP) has been calculated to be in the range 8–15% in a UK primary care population and 5–7% in a US population-based cohort. IBP rates are significantly higher in patients with psoriasis, uveitis, or inflammatory bowel disease than the general population. There is a paucity of good epidemiological studies to define the true incidence and prevalence of ankylosing spondylitis (AS), axial spondyloarthritis (axSpA), and spondyloarthritis (SpA), with wide variation as a result of geographic, demographic and methodological factors. The global prevalence estimates range from 0.01–0.2% for AS, to 0.32–0.7% for axSpA and around 1% for SpA overall. The global incidence estimates range from 0.44–7.3 cases per 100,000 person-years for AS to 0.48–62.5 cases per 100,000 person-years in SpA. The demographics and natural history of disease progression are also discussed.

Sign In

Copyright © 2021. All rights reserved.